nodes	percent_of_prediction	percent_of_DWPC	metapath
Lidocaine—EGFR—esophageal cancer	0.342	0.472	CbGaD
Lidocaine—CYP2A6—esophageal cancer	0.279	0.385	CbGaD
Lidocaine—ABCB1—esophageal cancer	0.104	0.143	CbGaD
Lidocaine—CYP2C9—Capecitabine—esophageal cancer	0.0158	0.306	CbGbCtD
Lidocaine—CYP2B6—Cisplatin—esophageal cancer	0.0151	0.292	CbGbCtD
Lidocaine—CYP2C9—Cisplatin—esophageal cancer	0.00798	0.154	CbGbCtD
Lidocaine—ABCB1—Cisplatin—esophageal cancer	0.00774	0.15	CbGbCtD
Lidocaine—Electric shock—Cisplatin—esophageal cancer	0.00649	0.0708	CcSEcCtD
Lidocaine—ABCB1—Methotrexate—esophageal cancer	0.00502	0.0972	CbGbCtD
Lidocaine—Apprehension—Cisplatin—esophageal cancer	0.00424	0.0463	CcSEcCtD
Lidocaine—Cranial nerve paralysis—Methotrexate—esophageal cancer	0.00387	0.0423	CcSEcCtD
Lidocaine—CNS toxicity—Methotrexate—esophageal cancer	0.00387	0.0423	CcSEcCtD
Lidocaine—Neurological symptom—Cisplatin—esophageal cancer	0.00269	0.0294	CcSEcCtD
Lidocaine—Meningism—Methotrexate—esophageal cancer	0.00257	0.0281	CcSEcCtD
Lidocaine—Arachnoiditis—Methotrexate—esophageal cancer	0.00244	0.0267	CcSEcCtD
Lidocaine—Hypoaesthesia oral—Capecitabine—esophageal cancer	0.0023	0.0251	CcSEcCtD
Lidocaine—Neurotoxicity—Cisplatin—esophageal cancer	0.0021	0.0229	CcSEcCtD
Lidocaine—Slurred speech—Cisplatin—esophageal cancer	0.00182	0.0199	CcSEcCtD
Lidocaine—Shivering—Capecitabine—esophageal cancer	0.00161	0.0176	CcSEcCtD
Lidocaine—Neurotoxicity—Capecitabine—esophageal cancer	0.00155	0.0169	CcSEcCtD
Lidocaine—Taste metallic—Methotrexate—esophageal cancer	0.0014	0.0153	CcSEcCtD
Lidocaine—Hoarseness—Capecitabine—esophageal cancer	0.00136	0.0149	CcSEcCtD
Lidocaine—Paraesthesia oral—Capecitabine—esophageal cancer	0.00128	0.014	CcSEcCtD
Lidocaine—Neurotoxicity—Methotrexate—esophageal cancer	0.00115	0.0126	CcSEcCtD
Lidocaine—Leukoderma—Methotrexate—esophageal cancer	0.00105	0.0115	CcSEcCtD
Lidocaine—Tenderness—Cisplatin—esophageal cancer	0.000932	0.0102	CcSEcCtD
Lidocaine—Dysarthria—Cisplatin—esophageal cancer	0.00086	0.00939	CcSEcCtD
Lidocaine—Pain—Carboplatin—esophageal cancer	0.000846	0.00924	CcSEcCtD
Lidocaine—Throat sore—Capecitabine—esophageal cancer	0.000832	0.00908	CcSEcCtD
Lidocaine—Blister—Capecitabine—esophageal cancer	0.000832	0.00908	CcSEcCtD
Lidocaine—Oropharyngeal discomfort—Capecitabine—esophageal cancer	0.000825	0.009	CcSEcCtD
Lidocaine—Ventricular fibrillation—Capecitabine—esophageal cancer	0.000783	0.00855	CcSEcCtD
Lidocaine—Skin exfoliation—Cisplatin—esophageal cancer	0.000777	0.00848	CcSEcCtD
Lidocaine—Hyperaesthesia—Capecitabine—esophageal cancer	0.000764	0.00834	CcSEcCtD
Lidocaine—Neuropathy—Cisplatin—esophageal cancer	0.000764	0.00834	CcSEcCtD
Lidocaine—Dysphonia—Capecitabine—esophageal cancer	0.000729	0.00796	CcSEcCtD
Lidocaine—Petechiae—Capecitabine—esophageal cancer	0.000729	0.00796	CcSEcCtD
Lidocaine—Contusion—Capecitabine—esophageal cancer	0.000687	0.0075	CcSEcCtD
Lidocaine—Oropharyngeal pain—Capecitabine—esophageal cancer	0.000659	0.0072	CcSEcCtD
Lidocaine—Paralysis—Methotrexate—esophageal cancer	0.000643	0.00702	CcSEcCtD
Lidocaine—Burning sensation—Methotrexate—esophageal cancer	0.000643	0.00702	CcSEcCtD
Lidocaine—Dysarthria—Capecitabine—esophageal cancer	0.000634	0.00692	CcSEcCtD
Lidocaine—Anaphylactoid reaction—Cisplatin—esophageal cancer	0.00061	0.00666	CcSEcCtD
Lidocaine—Urinary incontinence—Capecitabine—esophageal cancer	0.000579	0.00632	CcSEcCtD
Lidocaine—Depressed level of consciousness—Capecitabine—esophageal cancer	0.000579	0.00632	CcSEcCtD
Lidocaine—Skin exfoliation—Capecitabine—esophageal cancer	0.000572	0.00625	CcSEcCtD
Lidocaine—Gingivitis—Methotrexate—esophageal cancer	0.000569	0.00621	CcSEcCtD
Lidocaine—Neuropathy—Capecitabine—esophageal cancer	0.000563	0.00615	CcSEcCtD
Lidocaine—Petechiae—Methotrexate—esophageal cancer	0.000543	0.00592	CcSEcCtD
Lidocaine—Apnoea—Methotrexate—esophageal cancer	0.000527	0.00575	CcSEcCtD
Lidocaine—Sweating increased—Cisplatin—esophageal cancer	0.000497	0.00543	CcSEcCtD
Lidocaine—Dysarthria—Methotrexate—esophageal cancer	0.000472	0.00515	CcSEcCtD
Lidocaine—Dermatitis bullous—Capecitabine—esophageal cancer	0.000455	0.00497	CcSEcCtD
Lidocaine—Neuropathy peripheral—Cisplatin—esophageal cancer	0.000446	0.00487	CcSEcCtD
Lidocaine—Stomatitis—Cisplatin—esophageal cancer	0.000444	0.00484	CcSEcCtD
Lidocaine—Diplopia—Capecitabine—esophageal cancer	0.000435	0.00475	CcSEcCtD
Lidocaine—Osteoarthritis—Capecitabine—esophageal cancer	0.000435	0.00475	CcSEcCtD
Lidocaine—Depressed level of consciousness—Methotrexate—esophageal cancer	0.000431	0.00471	CcSEcCtD
Lidocaine—Skin exfoliation—Methotrexate—esophageal cancer	0.000426	0.00465	CcSEcCtD
Lidocaine—Bradycardia—Cisplatin—esophageal cancer	0.000416	0.00454	CcSEcCtD
Lidocaine—Cardiac arrest—Capecitabine—esophageal cancer	0.000414	0.00452	CcSEcCtD
Lidocaine—Urinary retention—Capecitabine—esophageal cancer	0.000414	0.00452	CcSEcCtD
Lidocaine—Coma—Methotrexate—esophageal cancer	0.000408	0.00445	CcSEcCtD
Lidocaine—Visual impairment—Cisplatin—esophageal cancer	0.000394	0.0043	CcSEcCtD
Lidocaine—Eye disorder—Cisplatin—esophageal cancer	0.000382	0.00417	CcSEcCtD
Lidocaine—Tinnitus—Cisplatin—esophageal cancer	0.000381	0.00416	CcSEcCtD
Lidocaine—Flushing—Cisplatin—esophageal cancer	0.000379	0.00414	CcSEcCtD
Lidocaine—Cardiac disorder—Cisplatin—esophageal cancer	0.000379	0.00414	CcSEcCtD
Lidocaine—Asthma—Capecitabine—esophageal cancer	0.000376	0.00411	CcSEcCtD
Lidocaine—Dysphagia—Capecitabine—esophageal cancer	0.000376	0.00411	CcSEcCtD
Lidocaine—Bronchospasm—Capecitabine—esophageal cancer	0.00037	0.00404	CcSEcCtD
Lidocaine—Immune system disorder—Cisplatin—esophageal cancer	0.000369	0.00403	CcSEcCtD
Lidocaine—Sweating increased—Capecitabine—esophageal cancer	0.000366	0.004	CcSEcCtD
Lidocaine—Erythema—Cisplatin—esophageal cancer	0.000356	0.00388	CcSEcCtD
Lidocaine—Visual disturbance—Methotrexate—esophageal cancer	0.000342	0.00373	CcSEcCtD
Lidocaine—Vision blurred—Cisplatin—esophageal cancer	0.000335	0.00366	CcSEcCtD
Lidocaine—Anaphylactoid reaction—Methotrexate—esophageal cancer	0.000335	0.00366	CcSEcCtD
Lidocaine—Tremor—Cisplatin—esophageal cancer	0.000333	0.00364	CcSEcCtD
Lidocaine—Neuropathy peripheral—Capecitabine—esophageal cancer	0.000329	0.00359	CcSEcCtD
Lidocaine—Stomatitis—Capecitabine—esophageal cancer	0.000327	0.00357	CcSEcCtD
Lidocaine—Osteoarthritis—Methotrexate—esophageal cancer	0.000324	0.00354	CcSEcCtD
Lidocaine—Convulsion—Cisplatin—esophageal cancer	0.000308	0.00336	CcSEcCtD
Lidocaine—Bradycardia—Capecitabine—esophageal cancer	0.000307	0.00335	CcSEcCtD
Lidocaine—Haemoglobin—Capecitabine—esophageal cancer	0.000303	0.0033	CcSEcCtD
Lidocaine—Rhinitis—Capecitabine—esophageal cancer	0.000302	0.0033	CcSEcCtD
Lidocaine—Anxiety—Cisplatin—esophageal cancer	0.000302	0.00329	CcSEcCtD
Lidocaine—Haemorrhage—Capecitabine—esophageal cancer	0.000301	0.00329	CcSEcCtD
Lidocaine—Hypoaesthesia—Capecitabine—esophageal cancer	0.0003	0.00327	CcSEcCtD
Lidocaine—Oedema—Cisplatin—esophageal cancer	0.00029	0.00317	CcSEcCtD
Lidocaine—Anaphylactic shock—Cisplatin—esophageal cancer	0.00029	0.00317	CcSEcCtD
Lidocaine—Visual impairment—Capecitabine—esophageal cancer	0.00029	0.00317	CcSEcCtD
Lidocaine—Nervous system disorder—Cisplatin—esophageal cancer	0.000285	0.00311	CcSEcCtD
Lidocaine—Eye disorder—Capecitabine—esophageal cancer	0.000281	0.00307	CcSEcCtD
Lidocaine—Tinnitus—Capecitabine—esophageal cancer	0.000281	0.00307	CcSEcCtD
Lidocaine—Hyperhidrosis—Cisplatin—esophageal cancer	0.000281	0.00306	CcSEcCtD
Lidocaine—Asthma—Methotrexate—esophageal cancer	0.00028	0.00306	CcSEcCtD
Lidocaine—Flushing—Capecitabine—esophageal cancer	0.000279	0.00305	CcSEcCtD
Lidocaine—Cardiac disorder—Capecitabine—esophageal cancer	0.000279	0.00305	CcSEcCtD
Lidocaine—Angiopathy—Capecitabine—esophageal cancer	0.000273	0.00298	CcSEcCtD
Lidocaine—Immune system disorder—Capecitabine—esophageal cancer	0.000272	0.00297	CcSEcCtD
Lidocaine—Hypotension—Cisplatin—esophageal cancer	0.000271	0.00296	CcSEcCtD
Lidocaine—Chills—Capecitabine—esophageal cancer	0.00027	0.00295	CcSEcCtD
Lidocaine—Erythema—Capecitabine—esophageal cancer	0.000262	0.00286	CcSEcCtD
Lidocaine—Paraesthesia—Cisplatin—esophageal cancer	0.000261	0.00285	CcSEcCtD
Lidocaine—Dyspnoea—Cisplatin—esophageal cancer	0.000259	0.00283	CcSEcCtD
Lidocaine—Dysgeusia—Capecitabine—esophageal cancer	0.000257	0.0028	CcSEcCtD
Lidocaine—Back pain—Capecitabine—esophageal cancer	0.000254	0.00277	CcSEcCtD
Lidocaine—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000251	0.00274	CcSEcCtD
Lidocaine—Drowsiness—Methotrexate—esophageal cancer	0.00025	0.00273	CcSEcCtD
Lidocaine—Pain—Cisplatin—esophageal cancer	0.000248	0.00271	CcSEcCtD
Lidocaine—Vision blurred—Capecitabine—esophageal cancer	0.000247	0.0027	CcSEcCtD
Lidocaine—Tremor—Capecitabine—esophageal cancer	0.000246	0.00268	CcSEcCtD
Lidocaine—Stomatitis—Methotrexate—esophageal cancer	0.000243	0.00266	CcSEcCtD
Lidocaine—Feeling abnormal—Cisplatin—esophageal cancer	0.000239	0.00261	CcSEcCtD
Lidocaine—Loss of consciousness—Capecitabine—esophageal cancer	0.00023	0.00252	CcSEcCtD
Lidocaine—Hypertension—Capecitabine—esophageal cancer	0.000226	0.00247	CcSEcCtD
Lidocaine—Haemoglobin—Methotrexate—esophageal cancer	0.000225	0.00246	CcSEcCtD
Lidocaine—Haemorrhage—Methotrexate—esophageal cancer	0.000224	0.00245	CcSEcCtD
Lidocaine—Chest pain—Capecitabine—esophageal cancer	0.000223	0.00244	CcSEcCtD
Lidocaine—Anxiety—Capecitabine—esophageal cancer	0.000222	0.00243	CcSEcCtD
Lidocaine—Visual impairment—Methotrexate—esophageal cancer	0.000216	0.00236	CcSEcCtD
Lidocaine—Confusional state—Capecitabine—esophageal cancer	0.000216	0.00236	CcSEcCtD
Lidocaine—Oedema—Capecitabine—esophageal cancer	0.000214	0.00234	CcSEcCtD
Lidocaine—Hypersensitivity—Cisplatin—esophageal cancer	0.000214	0.00233	CcSEcCtD
Lidocaine—Shock—Capecitabine—esophageal cancer	0.00021	0.0023	CcSEcCtD
Lidocaine—Nervous system disorder—Capecitabine—esophageal cancer	0.00021	0.00229	CcSEcCtD
Lidocaine—Eye disorder—Methotrexate—esophageal cancer	0.000209	0.00229	CcSEcCtD
Lidocaine—Tinnitus—Methotrexate—esophageal cancer	0.000209	0.00228	CcSEcCtD
Lidocaine—Asthenia—Cisplatin—esophageal cancer	0.000208	0.00227	CcSEcCtD
Lidocaine—Cardiac disorder—Methotrexate—esophageal cancer	0.000208	0.00227	CcSEcCtD
Lidocaine—Hyperhidrosis—Capecitabine—esophageal cancer	0.000207	0.00226	CcSEcCtD
Lidocaine—Angiopathy—Methotrexate—esophageal cancer	0.000203	0.00222	CcSEcCtD
Lidocaine—Immune system disorder—Methotrexate—esophageal cancer	0.000202	0.00221	CcSEcCtD
Lidocaine—Chills—Methotrexate—esophageal cancer	0.000201	0.0022	CcSEcCtD
Lidocaine—Hypotension—Capecitabine—esophageal cancer	0.0002	0.00218	CcSEcCtD
Lidocaine—Erythema—Methotrexate—esophageal cancer	0.000195	0.00213	CcSEcCtD
Lidocaine—Paraesthesia—Capecitabine—esophageal cancer	0.000192	0.0021	CcSEcCtD
Lidocaine—Dysgeusia—Methotrexate—esophageal cancer	0.000191	0.00209	CcSEcCtD
Lidocaine—Dyspnoea—Capecitabine—esophageal cancer	0.000191	0.00208	CcSEcCtD
Lidocaine—Back pain—Methotrexate—esophageal cancer	0.000189	0.00206	CcSEcCtD
Lidocaine—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000185	0.00202	CcSEcCtD
Lidocaine—Vomiting—Cisplatin—esophageal cancer	0.000185	0.00201	CcSEcCtD
Lidocaine—Vision blurred—Methotrexate—esophageal cancer	0.000184	0.00201	CcSEcCtD
Lidocaine—Rash—Cisplatin—esophageal cancer	0.000183	0.002	CcSEcCtD
Lidocaine—Pain—Capecitabine—esophageal cancer	0.000183	0.002	CcSEcCtD
Lidocaine—Dermatitis—Cisplatin—esophageal cancer	0.000183	0.002	CcSEcCtD
Lidocaine—Feeling abnormal—Capecitabine—esophageal cancer	0.000176	0.00193	CcSEcCtD
Lidocaine—Nausea—Cisplatin—esophageal cancer	0.000172	0.00188	CcSEcCtD
Lidocaine—Urticaria—Capecitabine—esophageal cancer	0.00017	0.00186	CcSEcCtD
Lidocaine—Convulsion—Methotrexate—esophageal cancer	0.000169	0.00185	CcSEcCtD
Lidocaine—Chest pain—Methotrexate—esophageal cancer	0.000166	0.00181	CcSEcCtD
Lidocaine—Confusional state—Methotrexate—esophageal cancer	0.000161	0.00175	CcSEcCtD
Lidocaine—Anaphylactic shock—Methotrexate—esophageal cancer	0.000159	0.00174	CcSEcCtD
Lidocaine—Hypersensitivity—Capecitabine—esophageal cancer	0.000158	0.00172	CcSEcCtD
Lidocaine—Nervous system disorder—Methotrexate—esophageal cancer	0.000156	0.00171	CcSEcCtD
Lidocaine—Hyperhidrosis—Methotrexate—esophageal cancer	0.000154	0.00168	CcSEcCtD
Lidocaine—Asthenia—Capecitabine—esophageal cancer	0.000153	0.00168	CcSEcCtD
Lidocaine—Hypotension—Methotrexate—esophageal cancer	0.000149	0.00163	CcSEcCtD
Lidocaine—Paraesthesia—Methotrexate—esophageal cancer	0.000143	0.00156	CcSEcCtD
Lidocaine—Dyspnoea—Methotrexate—esophageal cancer	0.000142	0.00155	CcSEcCtD
Lidocaine—Somnolence—Methotrexate—esophageal cancer	0.000142	0.00155	CcSEcCtD
Lidocaine—Dizziness—Capecitabine—esophageal cancer	0.000141	0.00154	CcSEcCtD
Lidocaine—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000137	0.0015	CcSEcCtD
Lidocaine—Pain—Methotrexate—esophageal cancer	0.000136	0.00149	CcSEcCtD
Lidocaine—Vomiting—Capecitabine—esophageal cancer	0.000136	0.00149	CcSEcCtD
Lidocaine—Rash—Capecitabine—esophageal cancer	0.000135	0.00147	CcSEcCtD
Lidocaine—Dermatitis—Capecitabine—esophageal cancer	0.000135	0.00147	CcSEcCtD
Lidocaine—Headache—Capecitabine—esophageal cancer	0.000134	0.00146	CcSEcCtD
Lidocaine—Feeling abnormal—Methotrexate—esophageal cancer	0.000131	0.00143	CcSEcCtD
Lidocaine—Nausea—Capecitabine—esophageal cancer	0.000127	0.00139	CcSEcCtD
Lidocaine—Urticaria—Methotrexate—esophageal cancer	0.000127	0.00138	CcSEcCtD
Lidocaine—Hypersensitivity—Methotrexate—esophageal cancer	0.000117	0.00128	CcSEcCtD
Lidocaine—Asthenia—Methotrexate—esophageal cancer	0.000114	0.00125	CcSEcCtD
Lidocaine—Dizziness—Methotrexate—esophageal cancer	0.000105	0.00115	CcSEcCtD
Lidocaine—Vomiting—Methotrexate—esophageal cancer	0.000101	0.00111	CcSEcCtD
Lidocaine—Rash—Methotrexate—esophageal cancer	0.0001	0.0011	CcSEcCtD
Lidocaine—Dermatitis—Methotrexate—esophageal cancer	0.0001	0.0011	CcSEcCtD
Lidocaine—Headache—Methotrexate—esophageal cancer	9.98e-05	0.00109	CcSEcCtD
Lidocaine—Nausea—Methotrexate—esophageal cancer	9.46e-05	0.00103	CcSEcCtD
Lidocaine—CYP2D6—Metabolism—TYMP—esophageal cancer	1.18e-05	8.97e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	1.18e-05	8.96e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—CYP2A6—esophageal cancer	1.18e-05	8.94e-05	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—CYP1B1—esophageal cancer	1.17e-05	8.94e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—TYMP—esophageal cancer	1.17e-05	8.89e-05	CbGpPWpGaD
Lidocaine—EGFR—Adaptive Immune System—CDKN1A—esophageal cancer	1.16e-05	8.85e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—GSTT1—esophageal cancer	1.16e-05	8.84e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—TLR4—esophageal cancer	1.15e-05	8.78e-05	CbGpPWpGaD
Lidocaine—EGFR—Innate Immune System—EP300—esophageal cancer	1.15e-05	8.77e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—CYP2A6—esophageal cancer	1.15e-05	8.74e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—CYP26A1—esophageal cancer	1.15e-05	8.72e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—CYP26A1—esophageal cancer	1.14e-05	8.65e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—NOTCH2—esophageal cancer	1.14e-05	8.64e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—GSTO1—esophageal cancer	1.13e-05	8.61e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—TPI1—esophageal cancer	1.13e-05	8.61e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—GNG7—esophageal cancer	1.13e-05	8.59e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—ALOX15—esophageal cancer	1.12e-05	8.5e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—PTGS1—esophageal cancer	1.11e-05	8.48e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—ENO1—esophageal cancer	1.11e-05	8.48e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—HIF1A—esophageal cancer	1.11e-05	8.48e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—ALOX15—esophageal cancer	1.11e-05	8.43e-05	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—CYP19A1—esophageal cancer	1.1e-05	8.4e-05	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—HMOX1—esophageal cancer	1.1e-05	8.36e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—PSME2—esophageal cancer	1.1e-05	8.36e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—PSME1—esophageal cancer	1.1e-05	8.36e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—PTGS1—esophageal cancer	1.09e-05	8.29e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—ENO1—esophageal cancer	1.09e-05	8.29e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—ALDOB—esophageal cancer	1.08e-05	8.25e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—SLC10A2—esophageal cancer	1.08e-05	8.23e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—CA1—esophageal cancer	1.08e-05	8.23e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—PSME2—esophageal cancer	1.07e-05	8.17e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—PSME1—esophageal cancer	1.07e-05	8.17e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—TPI1—esophageal cancer	1.07e-05	8.11e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—GSTO1—esophageal cancer	1.07e-05	8.11e-05	CbGpPWpGaD
Lidocaine—CYP2C18—Metabolism—CREBBP—esophageal cancer	1.06e-05	8.07e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—ALDH2—esophageal cancer	1.06e-05	8.05e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—GSTO1—esophageal cancer	1.06e-05	8.04e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—TPI1—esophageal cancer	1.06e-05	8.04e-05	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—ABCB1—esophageal cancer	1.05e-05	8.03e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—ADH1B—esophageal cancer	1.04e-05	7.95e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—GAPDH—esophageal cancer	1.04e-05	7.94e-05	CbGpPWpGaD
Lidocaine—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	1.04e-05	7.93e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—CRABP1—esophageal cancer	1.03e-05	7.87e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—ALDOB—esophageal cancer	1.02e-05	7.78e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—NOS2—esophageal cancer	1.01e-05	7.71e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—ALDOB—esophageal cancer	1.01e-05	7.71e-05	CbGpPWpGaD
Lidocaine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	1.01e-05	7.67e-05	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—HMOX1—esophageal cancer	1.01e-05	7.67e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—TGFBR2—esophageal cancer	1.01e-05	7.66e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—GSTT1—esophageal cancer	1.01e-05	7.66e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—NOTCH1—esophageal cancer	1e-05	7.64e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—TYMP—esophageal cancer	9.98e-06	7.6e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—CYP2A6—esophageal cancer	9.95e-06	7.57e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	9.91e-06	7.54e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—CASP8—esophageal cancer	9.9e-06	7.53e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—CA2—esophageal cancer	9.89e-06	7.53e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—CREBBP—esophageal cancer	9.85e-06	7.5e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—GNG7—esophageal cancer	9.84e-06	7.49e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—GAPDH—esophageal cancer	9.84e-06	7.49e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—GAPDH—esophageal cancer	9.75e-06	7.42e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—CRABP1—esophageal cancer	9.75e-06	7.42e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—CYP26A1—esophageal cancer	9.71e-06	7.39e-05	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—ABCB1—esophageal cancer	9.67e-06	7.36e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—CRABP1—esophageal cancer	9.66e-06	7.35e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—SMAD4—esophageal cancer	9.53e-06	7.25e-05	CbGpPWpGaD
Lidocaine—CYP2C18—Metabolism—NOS3—esophageal cancer	9.5e-06	7.23e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—CYP1B1—esophageal cancer	9.47e-06	7.21e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—ALOX15—esophageal cancer	9.46e-06	7.2e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—PTGS1—esophageal cancer	9.43e-06	7.18e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—ENO1—esophageal cancer	9.43e-06	7.18e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—PSME2—esophageal cancer	9.29e-06	7.07e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—PSME1—esophageal cancer	9.29e-06	7.07e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—GNG7—esophageal cancer	9.27e-06	7.06e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—CYP1B1—esophageal cancer	9.26e-06	7.05e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—ALDH2—esophageal cancer	9.22e-06	7.02e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—PLCE1—esophageal cancer	9.19e-06	7e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—ADH7—esophageal cancer	9.19e-06	7e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—GNG7—esophageal cancer	9.19e-06	7e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—CREBBP—esophageal cancer	9.1e-06	6.92e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—GSTO1—esophageal cancer	9.03e-06	6.87e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—TPI1—esophageal cancer	9.03e-06	6.87e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—CYP19A1—esophageal cancer	8.91e-06	6.78e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—GSTT1—esophageal cancer	8.77e-06	6.67e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—CYP19A1—esophageal cancer	8.71e-06	6.63e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—ALDH2—esophageal cancer	8.69e-06	6.61e-05	CbGpPWpGaD
Lidocaine—CYP2C18—Metabolism—PTGS2—esophageal cancer	8.68e-06	6.61e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—CYP2A6—esophageal cancer	8.67e-06	6.6e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—ALDOB—esophageal cancer	8.66e-06	6.59e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—ALDH2—esophageal cancer	8.61e-06	6.55e-05	CbGpPWpGaD
Lidocaine—EGFR—Innate Immune System—PIK3CA—esophageal cancer	8.52e-06	6.49e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—BCL2—esophageal cancer	8.49e-06	6.46e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—GAPDH—esophageal cancer	8.33e-06	6.34e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—GSTT1—esophageal cancer	8.26e-06	6.29e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—CRABP1—esophageal cancer	8.26e-06	6.28e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—ERBB2—esophageal cancer	8.25e-06	6.28e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—ENO1—esophageal cancer	8.22e-06	6.25e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—PTGS1—esophageal cancer	8.22e-06	6.25e-05	CbGpPWpGaD
Lidocaine—ABCB1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	8.21e-06	6.25e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—GSTT1—esophageal cancer	8.19e-06	6.23e-05	CbGpPWpGaD
Lidocaine—EGFR—Adaptive Immune System—PIK3CA—esophageal cancer	8.18e-06	6.23e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—CYP2A6—esophageal cancer	8.17e-06	6.22e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—NOS3—esophageal cancer	8.15e-06	6.2e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—HMOX1—esophageal cancer	8.13e-06	6.19e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	8.12e-06	6.18e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—CYP2A6—esophageal cancer	8.1e-06	6.16e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—PSME2—esophageal cancer	8.1e-06	6.16e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—PSME1—esophageal cancer	8.1e-06	6.16e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	8.07e-06	6.14e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—ADH1B—esophageal cancer	8.06e-06	6.14e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—CYP1B1—esophageal cancer	8.02e-06	6.1e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—HMOX1—esophageal cancer	7.94e-06	6.05e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—GNG7—esophageal cancer	7.85e-06	5.98e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—ABCB1—esophageal cancer	7.8e-06	5.94e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—HIF1A—esophageal cancer	7.8e-06	5.94e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—PTGS1—esophageal cancer	7.74e-06	5.89e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—ENO1—esophageal cancer	7.74e-06	5.89e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—TYMP—esophageal cancer	7.71e-06	5.86e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—ENO1—esophageal cancer	7.68e-06	5.84e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—PTGS1—esophageal cancer	7.68e-06	5.84e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—PSME2—esophageal cancer	7.63e-06	5.81e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—PSME1—esophageal cancer	7.63e-06	5.81e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—ABCB1—esophageal cancer	7.63e-06	5.8e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—ERBB2—esophageal cancer	7.62e-06	5.8e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—PSME1—esophageal cancer	7.56e-06	5.76e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—PSME2—esophageal cancer	7.56e-06	5.76e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—CYP19A1—esophageal cancer	7.54e-06	5.74e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—CYP26A1—esophageal cancer	7.5e-06	5.7e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—KDR—esophageal cancer	7.46e-06	5.68e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—PTGS2—esophageal cancer	7.45e-06	5.67e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—ALDH2—esophageal cancer	7.36e-06	5.6e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—ALOX15—esophageal cancer	7.3e-06	5.56e-05	CbGpPWpGaD
Lidocaine—CYP2C18—Metabolism—EP300—esophageal cancer	7.22e-06	5.5e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—CDKN1A—esophageal cancer	7.05e-06	5.37e-05	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—CREBBP—esophageal cancer	7.05e-06	5.37e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—NOTCH1—esophageal cancer	7.03e-06	5.35e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—GSTT1—esophageal cancer	7e-06	5.33e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—CYP1B1—esophageal cancer	6.99e-06	5.32e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—TPI1—esophageal cancer	6.97e-06	5.3e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—GSTO1—esophageal cancer	6.97e-06	5.3e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—CYP2A6—esophageal cancer	6.92e-06	5.27e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	6.89e-06	5.25e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—HMOX1—esophageal cancer	6.88e-06	5.24e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	6.75e-06	5.14e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—EP300—esophageal cancer	6.71e-06	5.11e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—ALDOB—esophageal cancer	6.68e-06	5.08e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	6.61e-06	5.03e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—ABCB1—esophageal cancer	6.6e-06	5.03e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—CYP1B1—esophageal cancer	6.58e-06	5.01e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—CYP19A1—esophageal cancer	6.57e-06	5e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—ENO1—esophageal cancer	6.56e-06	4.99e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—PTGS1—esophageal cancer	6.56e-06	4.99e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—CYP1B1—esophageal cancer	6.53e-06	4.97e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—CDKN1A—esophageal cancer	6.51e-06	4.96e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—PSME2—esophageal cancer	6.46e-06	4.92e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—PSME1—esophageal cancer	6.46e-06	4.92e-05	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—CREBBP—esophageal cancer	6.46e-06	4.92e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—GAPDH—esophageal cancer	6.43e-06	4.89e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—CRABP1—esophageal cancer	6.37e-06	4.85e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—CREBBP—esophageal cancer	6.37e-06	4.85e-05	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—NOS3—esophageal cancer	6.31e-06	4.8e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—EP300—esophageal cancer	6.2e-06	4.72e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—CYP19A1—esophageal cancer	6.19e-06	4.71e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—CYP19A1—esophageal cancer	6.14e-06	4.67e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—GNG7—esophageal cancer	6.06e-06	4.61e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—HMOX1—esophageal cancer	5.99e-06	4.56e-05	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—NOS3—esophageal cancer	5.79e-06	4.4e-05	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—PTGS2—esophageal cancer	5.77e-06	4.39e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—NOS3—esophageal cancer	5.7e-06	4.34e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—ALDH2—esophageal cancer	5.68e-06	4.32e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—HMOX1—esophageal cancer	5.65e-06	4.3e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	5.64e-06	4.3e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—HMOX1—esophageal cancer	5.6e-06	4.26e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—CYP1B1—esophageal cancer	5.58e-06	4.25e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	5.49e-06	4.18e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling by GPCR—PIK3CA—esophageal cancer	5.43e-06	4.13e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—ABCB1—esophageal cancer	5.42e-06	4.13e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—GSTT1—esophageal cancer	5.4e-06	4.11e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—MYC—esophageal cancer	5.4e-06	4.11e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—ABCB1—esophageal cancer	5.38e-06	4.09e-05	CbGpPWpGaD
Lidocaine—CYP2C18—Metabolism—PIK3CA—esophageal cancer	5.34e-06	4.07e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—CYP2A6—esophageal cancer	5.34e-06	4.06e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—ERBB2—esophageal cancer	5.34e-06	4.06e-05	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—PTGS2—esophageal cancer	5.29e-06	4.03e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—CYP19A1—esophageal cancer	5.24e-06	3.99e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—CREBBP—esophageal cancer	5.21e-06	3.97e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—CREBBP—esophageal cancer	5.1e-06	3.88e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—ENO1—esophageal cancer	5.06e-06	3.85e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—PTGS1—esophageal cancer	5.06e-06	3.85e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	4.99e-06	3.8e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—PSME2—esophageal cancer	4.99e-06	3.8e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—PSME1—esophageal cancer	4.99e-06	3.8e-05	CbGpPWpGaD
Lidocaine—EGFR—Immune System—PIK3CA—esophageal cancer	4.96e-06	3.78e-05	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—EP300—esophageal cancer	4.8e-06	3.65e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—HMOX1—esophageal cancer	4.79e-06	3.64e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—CCND1—esophageal cancer	4.71e-06	3.59e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	4.69e-06	3.57e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—NOS3—esophageal cancer	4.67e-06	3.55e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—ABCB1—esophageal cancer	4.59e-06	3.5e-05	CbGpPWpGaD
Lidocaine—EGFR—Disease—PIK3CA—esophageal cancer	4.58e-06	3.49e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—NOS3—esophageal cancer	4.56e-06	3.47e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—CDKN1A—esophageal cancer	4.56e-06	3.47e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—CREBBP—esophageal cancer	4.41e-06	3.36e-05	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—EP300—esophageal cancer	4.4e-06	3.35e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—EP300—esophageal cancer	4.34e-06	3.3e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—CYP1B1—esophageal cancer	4.3e-06	3.28e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—PTGS2—esophageal cancer	4.27e-06	3.25e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—PTGS2—esophageal cancer	4.17e-06	3.18e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	4.06e-06	3.09e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—CYP19A1—esophageal cancer	4.05e-06	3.08e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—NOS3—esophageal cancer	3.95e-06	3.01e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—CREBBP—esophageal cancer	3.85e-06	2.93e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—MYC—esophageal cancer	3.78e-06	2.88e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—HMOX1—esophageal cancer	3.69e-06	2.81e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—CREBBP—esophageal cancer	3.62e-06	2.76e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—PTGS2—esophageal cancer	3.61e-06	2.75e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—CREBBP—esophageal cancer	3.59e-06	2.73e-05	CbGpPWpGaD
Lidocaine—CYP3A7—Metabolism—PIK3CA—esophageal cancer	3.55e-06	2.7e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—EP300—esophageal cancer	3.55e-06	2.7e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—ABCB1—esophageal cancer	3.55e-06	2.7e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	3.47e-06	2.64e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—EP300—esophageal cancer	3.47e-06	2.64e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—NOS3—esophageal cancer	3.44e-06	2.62e-05	CbGpPWpGaD
Lidocaine—CYP2A6—Metabolism—PIK3CA—esophageal cancer	3.26e-06	2.48e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—NOS3—esophageal cancer	3.24e-06	2.47e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—NOS3—esophageal cancer	3.22e-06	2.45e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—PIK3CA—esophageal cancer	3.21e-06	2.44e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—PTGS2—esophageal cancer	3.15e-06	2.4e-05	CbGpPWpGaD
Lidocaine—EGFR—Signaling Pathways—TP53—esophageal cancer	3.11e-06	2.36e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—CREBBP—esophageal cancer	3.07e-06	2.34e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—EP300—esophageal cancer	3.01e-06	2.29e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—PTGS2—esophageal cancer	2.97e-06	2.26e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—PTGS2—esophageal cancer	2.94e-06	2.24e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—NOS3—esophageal cancer	2.75e-06	2.09e-05	CbGpPWpGaD
Lidocaine—CYP2B6—Metabolism—PIK3CA—esophageal cancer	2.63e-06	2e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—EP300—esophageal cancer	2.62e-06	1.99e-05	CbGpPWpGaD
Lidocaine—CYP3A5—Metabolism—PIK3CA—esophageal cancer	2.57e-06	1.95e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—PTGS2—esophageal cancer	2.51e-06	1.91e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—EP300—esophageal cancer	2.47e-06	1.88e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—EP300—esophageal cancer	2.45e-06	1.86e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—CREBBP—esophageal cancer	2.37e-06	1.8e-05	CbGpPWpGaD
Lidocaine—CYP2C8—Metabolism—PIK3CA—esophageal cancer	2.22e-06	1.69e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—NOS3—esophageal cancer	2.12e-06	1.61e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—EP300—esophageal cancer	2.09e-06	1.59e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—PTGS2—esophageal cancer	1.94e-06	1.48e-05	CbGpPWpGaD
Lidocaine—ABCB1—Metabolism—PIK3CA—esophageal cancer	1.94e-06	1.47e-05	CbGpPWpGaD
Lidocaine—CYP2D6—Metabolism—PIK3CA—esophageal cancer	1.83e-06	1.39e-05	CbGpPWpGaD
Lidocaine—CYP2C9—Metabolism—PIK3CA—esophageal cancer	1.81e-06	1.38e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—EP300—esophageal cancer	1.61e-06	1.23e-05	CbGpPWpGaD
Lidocaine—CYP1A2—Metabolism—PIK3CA—esophageal cancer	1.55e-06	1.18e-05	CbGpPWpGaD
Lidocaine—CYP3A4—Metabolism—PIK3CA—esophageal cancer	1.19e-06	9.08e-06	CbGpPWpGaD
